Therapeutic strategies for tauopathies and drug repurposing as a potential approach
[Display omitted] Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive eff...
Gespeichert in:
| Veröffentlicht in: | Biochemical pharmacology 2022-04, Vol.198, p.114979-114979, Article 114979 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114979 |
|---|---|
| container_issue | |
| container_start_page | 114979 |
| container_title | Biochemical pharmacology |
| container_volume | 198 |
| creator | Islam, Majedul Shen, Fengyun Regmi, Deepika Du, Deguo |
| description | [Display omitted]
Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive efforts have been provided to develop disease-modifying therapies to treat tauopathies. Specifically, exploring existing drugs with the intent of repurposing for the treatment of tauopathies affords a reasonable alternative to discover potent drugs for treating these formidable diseases. Drug repurposing will not only reduce formulation and development stage effort and cost but will also take a key advantage of the established toxicological studies, which is one of the main causes of clinical trial failure of new molecules. In this review, we provide an overview of the current treatment strategies for tauopathies and the recent progress in drug repurposing as an alternative approach to treat tauopathies. |
| doi_str_mv | 10.1016/j.bcp.2022.114979 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9159505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295222000739</els_id><sourcerecordid>2634528918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-b1d0abf276f34476040ef745c2ca8d1d42d4beedf0fba077b71b03906270be5b3</originalsourceid><addsrcrecordid>eNp9UU1P3DAQtaoiWCg_oJcqRy67jJ04ToSEVKEWkJA4QM-WPya7XmVj13aQ-Pf1aikql57m682bp3mEfKWwokDby-1Km7BiwNiK0qYX_SeyoJ2ol6xvu89kAQBtyTk7Iacpbfdl19JjclJzRnsBdEGenjcYVcA5O1OlHFXGtcNUDT5WWc0-qLzZ12qylY3zuooY5hh8ctO6UqVfBZ9xyk6NlQohemU2X8jRoMaE52_xjPz6-eP55m758Hh7f_P9YWk4FXmpqQWlBybaoW4a0UIDOIiGG2ZUZ6ltmG00oh1g0AqE0IJqqHtomQCNXNdn5PrAG2a9Q2uKjKhGGaLbqfgqvXLy42RyG7n2L7KnvOfAC8HFG0H0v2dMWe5cMjiOakI_J8nauuGs62lXoPQANdGnFHF4P0NB7s2QW1nMkHsz5MGMsvPtX33vG3-_XwBXBwCWL704jDIZh5NB6yKaLK13_6H_AyiunNA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634528918</pqid></control><display><type>article</type><title>Therapeutic strategies for tauopathies and drug repurposing as a potential approach</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Islam, Majedul ; Shen, Fengyun ; Regmi, Deepika ; Du, Deguo</creator><creatorcontrib>Islam, Majedul ; Shen, Fengyun ; Regmi, Deepika ; Du, Deguo</creatorcontrib><description>[Display omitted]
Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive efforts have been provided to develop disease-modifying therapies to treat tauopathies. Specifically, exploring existing drugs with the intent of repurposing for the treatment of tauopathies affords a reasonable alternative to discover potent drugs for treating these formidable diseases. Drug repurposing will not only reduce formulation and development stage effort and cost but will also take a key advantage of the established toxicological studies, which is one of the main causes of clinical trial failure of new molecules. In this review, we provide an overview of the current treatment strategies for tauopathies and the recent progress in drug repurposing as an alternative approach to treat tauopathies.</description><identifier>ISSN: 0006-2952</identifier><identifier>ISSN: 1873-2968</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2022.114979</identifier><identifier>PMID: 35219701</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer's disease (AD), Neurofibrillary tangles (NFTs) ; Brain - metabolism ; Drug Repositioning ; Humans ; Microtubule (MT) ; Phosphorylated tau (p-tau) ; Post-translational modifications (PTMs) ; Repurposing ; Tau ; tau Proteins - metabolism ; Tauopathies - drug therapy ; Tauopathy</subject><ispartof>Biochemical pharmacology, 2022-04, Vol.198, p.114979-114979, Article 114979</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-b1d0abf276f34476040ef745c2ca8d1d42d4beedf0fba077b71b03906270be5b3</citedby><cites>FETCH-LOGICAL-c517t-b1d0abf276f34476040ef745c2ca8d1d42d4beedf0fba077b71b03906270be5b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006295222000739$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35219701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Islam, Majedul</creatorcontrib><creatorcontrib>Shen, Fengyun</creatorcontrib><creatorcontrib>Regmi, Deepika</creatorcontrib><creatorcontrib>Du, Deguo</creatorcontrib><title>Therapeutic strategies for tauopathies and drug repurposing as a potential approach</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>[Display omitted]
Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive efforts have been provided to develop disease-modifying therapies to treat tauopathies. Specifically, exploring existing drugs with the intent of repurposing for the treatment of tauopathies affords a reasonable alternative to discover potent drugs for treating these formidable diseases. Drug repurposing will not only reduce formulation and development stage effort and cost but will also take a key advantage of the established toxicological studies, which is one of the main causes of clinical trial failure of new molecules. In this review, we provide an overview of the current treatment strategies for tauopathies and the recent progress in drug repurposing as an alternative approach to treat tauopathies.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease (AD), Neurofibrillary tangles (NFTs)</subject><subject>Brain - metabolism</subject><subject>Drug Repositioning</subject><subject>Humans</subject><subject>Microtubule (MT)</subject><subject>Phosphorylated tau (p-tau)</subject><subject>Post-translational modifications (PTMs)</subject><subject>Repurposing</subject><subject>Tau</subject><subject>tau Proteins - metabolism</subject><subject>Tauopathies - drug therapy</subject><subject>Tauopathy</subject><issn>0006-2952</issn><issn>1873-2968</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1P3DAQtaoiWCg_oJcqRy67jJ04ToSEVKEWkJA4QM-WPya7XmVj13aQ-Pf1aikql57m682bp3mEfKWwokDby-1Km7BiwNiK0qYX_SeyoJ2ol6xvu89kAQBtyTk7Iacpbfdl19JjclJzRnsBdEGenjcYVcA5O1OlHFXGtcNUDT5WWc0-qLzZ12qylY3zuooY5hh8ctO6UqVfBZ9xyk6NlQohemU2X8jRoMaE52_xjPz6-eP55m758Hh7f_P9YWk4FXmpqQWlBybaoW4a0UIDOIiGG2ZUZ6ltmG00oh1g0AqE0IJqqHtomQCNXNdn5PrAG2a9Q2uKjKhGGaLbqfgqvXLy42RyG7n2L7KnvOfAC8HFG0H0v2dMWe5cMjiOakI_J8nauuGs62lXoPQANdGnFHF4P0NB7s2QW1nMkHsz5MGMsvPtX33vG3-_XwBXBwCWL704jDIZh5NB6yKaLK13_6H_AyiunNA</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Islam, Majedul</creator><creator>Shen, Fengyun</creator><creator>Regmi, Deepika</creator><creator>Du, Deguo</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220401</creationdate><title>Therapeutic strategies for tauopathies and drug repurposing as a potential approach</title><author>Islam, Majedul ; Shen, Fengyun ; Regmi, Deepika ; Du, Deguo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-b1d0abf276f34476040ef745c2ca8d1d42d4beedf0fba077b71b03906270be5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease (AD), Neurofibrillary tangles (NFTs)</topic><topic>Brain - metabolism</topic><topic>Drug Repositioning</topic><topic>Humans</topic><topic>Microtubule (MT)</topic><topic>Phosphorylated tau (p-tau)</topic><topic>Post-translational modifications (PTMs)</topic><topic>Repurposing</topic><topic>Tau</topic><topic>tau Proteins - metabolism</topic><topic>Tauopathies - drug therapy</topic><topic>Tauopathy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Islam, Majedul</creatorcontrib><creatorcontrib>Shen, Fengyun</creatorcontrib><creatorcontrib>Regmi, Deepika</creatorcontrib><creatorcontrib>Du, Deguo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Islam, Majedul</au><au>Shen, Fengyun</au><au>Regmi, Deepika</au><au>Du, Deguo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic strategies for tauopathies and drug repurposing as a potential approach</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>198</volume><spage>114979</spage><epage>114979</epage><pages>114979-114979</pages><artnum>114979</artnum><issn>0006-2952</issn><issn>1873-2968</issn><eissn>1873-2968</eissn><abstract>[Display omitted]
Tauopathies are neurodegenerative diseases characterized by the deposition of abnormal tau in the brain. To date, there are no disease-modifying therapies approved by the U.S. Food and Drug Administration (US FDA) for the treatment of tauopathies. In the past decades, extensive efforts have been provided to develop disease-modifying therapies to treat tauopathies. Specifically, exploring existing drugs with the intent of repurposing for the treatment of tauopathies affords a reasonable alternative to discover potent drugs for treating these formidable diseases. Drug repurposing will not only reduce formulation and development stage effort and cost but will also take a key advantage of the established toxicological studies, which is one of the main causes of clinical trial failure of new molecules. In this review, we provide an overview of the current treatment strategies for tauopathies and the recent progress in drug repurposing as an alternative approach to treat tauopathies.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>35219701</pmid><doi>10.1016/j.bcp.2022.114979</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-2952 |
| ispartof | Biochemical pharmacology, 2022-04, Vol.198, p.114979-114979, Article 114979 |
| issn | 0006-2952 1873-2968 1873-2968 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9159505 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Alzheimer Disease - drug therapy Alzheimer's disease (AD), Neurofibrillary tangles (NFTs) Brain - metabolism Drug Repositioning Humans Microtubule (MT) Phosphorylated tau (p-tau) Post-translational modifications (PTMs) Repurposing Tau tau Proteins - metabolism Tauopathies - drug therapy Tauopathy |
| title | Therapeutic strategies for tauopathies and drug repurposing as a potential approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A34%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20strategies%20for%20tauopathies%20and%20drug%20repurposing%20as%20a%20potential%20approach&rft.jtitle=Biochemical%20pharmacology&rft.au=Islam,%20Majedul&rft.date=2022-04-01&rft.volume=198&rft.spage=114979&rft.epage=114979&rft.pages=114979-114979&rft.artnum=114979&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2022.114979&rft_dat=%3Cproquest_pubme%3E2634528918%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634528918&rft_id=info:pmid/35219701&rft_els_id=S0006295222000739&rfr_iscdi=true |